STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1621 by analyst upside · 2026-06-27
STOK
Stoke Therapeutics, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+40.9%
implied upside to consensus target
Current Price $32.0
Consensus Target $45.1
Bull Target $60.0
Bear Target $35.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
9
Hold
0
Sell
0
52-Week Low $11.19
52-Week High $40.22
YTD Return +3.6%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -10.3x
EPS (TTM) $-2.86
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $32M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $11.19
52-Week High $40.22
Current Price $32.0
Bear Target $35.0
Bull Target $60.0
● Now $32.0 ● Target $45.1
TRADING DATA
Avg Volume 600K
YTD Return +3.6%
Analyst Count 10
Consensus Buy
Upside to Target +40.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Stoke Therapeutics, Inc. (STOK) is currently trading at $32.0 with a Wall Street consensus price target of $45.1, implying potential upside of 40.9% over the next 12 months. 10 analysts currently cover STOK, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $60.0, while the most cautious has a target of $35.0.

STOK operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 3.6% year-to-date and is currently trading near the upper end of its 52-week range of $11.19 – $40.22.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for STOK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG reit
Buy → Buy 2026-05-11 38% win rate (8 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-03-20 Building track record
BTIG reit
Buy → Buy 2026-03-19 38% win rate (8 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-03-18 Building track record
Chardan Capital — Reiterated
Buy → Buy 2026-03-18 33% win rate (6 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-03-17 Building track record
Needham — Reiterated
Buy → Buy 2026-03-17 20% win rate (5 calls)
Wolfe Research ● Initiated
Outperform 2026-02-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
18/30
Consensus clarity
14/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →